{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:04:15Z","timestamp":1790661855976,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Increasing evidence implicates gut dysbiosis in the pathophysiology of advanced cirrhosis. This is an ancillary study of the ProPILA-Rifax trial (NCT03069131), which evaluated rifaximin (RFX) as primary prophylaxis of spontaneous bacterial peritonitis (SBP) in patients with severe cirrhosis. Although the combined use of RFX and lactulose is effective in preventing recurrent hepatic encephalopathy (HE), its longitudinal impact on microbial communities and antibiotic resistance remains poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We characterized longitudinal changes in the gut microbiome of 42 patients (21 RFX, 21 placebo) over 12 months using 16S rRNA gene sequencing and culture-based phenotypic susceptibility testing. Exploratory analyses between patient bacterial profiles and clinical outcomes (disease severity, overall survival, and incidence of SBP) were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      RFX treatment reduced microbial richness and decreased the abundance of taxa typically enriched in advanced cirrhosis (e.g.,\n                      <jats:italic>Escherichia<\/jats:italic>\n                      ,\n                      <jats:italic>Streptococcus<\/jats:italic>\n                      ,\n                      <jats:italic>Veillonella<\/jats:italic>\n                      ). RFX increased the proportion of Escherichia coli isolates exhibiting phenotypic resistance to rifampicin, without observed cross-resistance to ciprofloxacin or cefotaxime. In exploratory analyses, a decrease in Child-Pugh scores was correlated with enrichment of commensal taxa. Moreover, higher abundances of Ruminococcus bromii and Blautia obeum at inclusion were respectively associated with improved 12-month survival and a lower incidence of SBP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      In severe cirrhosis, RFX profoundly alters gut microbial composition by reducing pathobiont abundance while promoting rifampicin resistance in\n                      <jats:italic>E. coli<\/jats:italic>\n                      . Furthermore, microbiota-derived signatures were associated with Child-Pugh scores, highlighting their potential to improve patient stratification.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1930709","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:50:15Z","timestamp":1790661015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gut microbial dynamics and antibiotic resistance during rifaximin therapy in severe cirrhosis: a ProPILA-Rifax ancillary study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ruben","family":"Ladeira","sequence":"first","affiliation":[{"name":"Bioinformatique et Big Data Au Service de La Sant\u00e9, Oncobiologie G\u00e9n\u00e9tique Bioinformatique, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]},{"name":"Universit\u00e9 Marie et Louis Pasteur, Centre National de la Recherche Scientifique (CNRS), Unit\u00e9 Mixte de Recherche (UMR) 6249 Chrono-environnement","place":["Besan\u00e7on, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Biguenet","sequence":"additional","affiliation":[{"name":"Bioinformatique et Big Data Au Service de La Sant\u00e9, Oncobiologie G\u00e9n\u00e9tique Bioinformatique, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]},{"name":"Universit\u00e9 Marie et Louis Pasteur, Centre National de la Recherche Scientifique (CNRS), Unit\u00e9 Mixte de Recherche (UMR) 6249 Chrono-environnement","place":["Besan\u00e7on, France"]},{"name":"Hygi\u00e8ne Hospitali\u00e8re, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Meunier","sequence":"additional","affiliation":[{"name":"Hygi\u00e8ne Hospitali\u00e8re, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Gonthier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Marie et Louis Pasteur, Centre National de la Recherche Scientifique (CNRS), Unit\u00e9 Mixte de Recherche (UMR) 6249 Chrono-environnement","place":["Besan\u00e7on, France"]},{"name":"Hygi\u00e8ne Hospitali\u00e8re, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Di Martino","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Marie et Louis Pasteur, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Unit\u00e9 Mixte de Recherche (UMR) 1098 Regulation of Immunity for therapeutic innovation in Graft, Host, Tumoral and inflammatory-associated diseases (RIGHT)","place":["Besan\u00e7on, France"]},{"name":"Service d\u2019H\u00e9patologie, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Pitta","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9pato-Gastroent\u00e9rologie, H\u00f4pital Cabrol","place":["Reims Cedex, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Bardou-Jacquet","sequence":"additional","affiliation":[{"name":"Univ. Rennes, Centre Hospitalier Universitaire (CHU) Rennes, Service des Maladies du Foie, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) 1241 Nutrition, M\u00e9tabolismes et Cancer (NUMECAN)","place":["Rennes, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Jolivet-Gougeon","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, Rennes University Hospital","place":["Rennes, France"]},{"name":"Univ. Rennes, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), INRAE, Unit\u00e9 Mixte de Recherche (UMR) S1230 Bacterial Regulatory RNAs & Medicine (BRM), Institut Nutrition, M\u00e9tabolismes et Cancer (NUMECAN) Unit\u00e9 Mixte de Recherche (UMR) 1241","place":["Rennes, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Desmarets","sequence":"additional","affiliation":[{"name":"Centre d\u2019Investigation Clinique 1431, unit\u00e9 de METhodologie (uMETh), Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]},{"name":"Universit\u00e9 Marie et Louis Pasteur, EFS, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Unit\u00e9 Mixte de Recherche (UMR) 1098 Regulation of Immunity for therapeutic innovation in Graft, Host, Tumoral and inflammatory-associated diseases (RIGHT)","place":["Besan\u00e7on, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Th\u00e9venot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Marie et Louis Pasteur, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Unit\u00e9 Mixte de Recherche (UMR) 1098 Regulation of Immunity for therapeutic innovation in Graft, Host, Tumoral and inflammatory-associated diseases (RIGHT)","place":["Besan\u00e7on, France"]},{"name":"Service d\u2019H\u00e9patologie, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Hocquet","sequence":"additional","affiliation":[{"name":"Bioinformatique et Big Data Au Service de La Sant\u00e9, Oncobiologie G\u00e9n\u00e9tique Bioinformatique, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]},{"name":"Universit\u00e9 Marie et Louis Pasteur, Centre National de la Recherche Scientifique (CNRS), Unit\u00e9 Mixte de Recherche (UMR) 6249 Chrono-environnement","place":["Besan\u00e7on, France"]},{"name":"Hygi\u00e8ne Hospitali\u00e8re, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Valot","sequence":"additional","affiliation":[{"name":"Bioinformatique et Big Data Au Service de La Sant\u00e9, Oncobiologie G\u00e9n\u00e9tique Bioinformatique, Centre Hospitalier Universitaire (CHU) Besan\u00e7on Franche-Comt\u00e9","place":["Besan\u00e7on, France"]},{"name":"Universit\u00e9 Marie et Louis Pasteur, Centre National de la Recherche Scientifique (CNRS), Unit\u00e9 Mixte de Recherche (UMR) 6249 Chrono-environnement","place":["Besan\u00e7on, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"B11","unstructured":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2024.12.047","article-title":"Microbiota transplant for hepatic encephalopathy in cirrhosis: the THEMATIC trial","volume":"83","author":"Bajaj","year":"2025","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3350\/cmh.2026.0228","article-title":"Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort","volume":"32","author":"Bajaj","year":"2026","journal-title":"Clin. Mol. Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/gutjnl-2020-322470","article-title":"Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy","volume":"70","author":"Bajaj","year":"2021","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.9593","article-title":"Improved normalization of species count data in ecology by scaling with ranked subsampling (SRS): application to microbial communities","volume":"8","author":"Beule","year":"2020","journal-title":"PeerJ"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100333","article-title":"Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy","volume":"25","author":"Bloom","year":"2021","journal-title":"Ann. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","article-title":"DADA2: high-resolution sample inference from Illumina amplicon data","volume":"13","author":"Callahan","year":"2016","journal-title":"Nat. Methods"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101896","article-title":"Sas20 is a highly flexible starch-binding protein in the Ruminococcus bromii cell-surface amylosome","volume":"298","author":"Cerqueira","year":"2022","journal-title":"J. Biol. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","article-title":"Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease","volume":"21","author":"Feng","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"12000","DOI":"10.1038\/s41598-019-48352-5","article-title":"Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis","volume":"9","author":"Horvath","year":"2019","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut\u2013liver axis and gut microbiota in health and liver disease","volume":"21","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0323359","article-title":"Efficacy and safety of rifaximin in preventing hepatic encephalopathy: a systematic review and meta-analysis","volume":"20","author":"Hu","year":"2025","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/liv.15207","article-title":"Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH)","volume":"42","author":"Jim\u00e9nez","year":"2022","journal-title":"Liver Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.3350\/cmh.2022.0351","article-title":"Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease","volume":"29","author":"Konyn","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1128\/AAC.02163-12","article-title":"Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-\u03b2-Naphthylamide-inhibitable efflux pumps","volume":"57","author":"Kothary","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67326-y","article-title":"Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin","volume":"17","author":"Kuo","year":"2025","journal-title":"Nat. Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jhep.2024.09.046","article-title":"Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance","volume":"82","author":"Lee","year":"2025","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1532599","article-title":"Ruminococcus bromii-generated acetate alleviated Clonorchis sinensis-induced liver fibrosis in mice","volume":"16","author":"Li","year":"2025","journal-title":"Front. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26991","article-title":"Short-chain fatty acids in nonalcoholic fatty liver disease: new prospects for short-chain fatty acids as therapeutic targets","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1875796","article-title":"Blautia-a new functional genus with potential probiotic properties","volume":"13","author":"Liu","year":"2021","journal-title":"Gut Microbes"},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3748\/wjg.v26.i2.199","article-title":"Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study","volume":"26","author":"Lv","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v112.i01","article-title":"Parsimoniously fitting large multivariate random effects in glmmTMB","volume":"112","author":"McGillycuddy","year":"2025","journal-title":"J. Stat. Software"},{"key":"B25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijsu.2011.10.001","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"10","author":"Moher","year":"2012","journal-title":"Int. J. Surg."},{"key":"B26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","article-title":"Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial","volume":"76","author":"Patel","year":"2022","journal-title":"J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1539972","article-title":"Role of short-chain fatty acids in non-alcoholic fatty liver disease and potential therapeutic targets","volume":"16","author":"Qin","year":"2025","journal-title":"Front. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gks1219","article-title":"The SILVA ribosomal RNA gene database project: improved data processing and web-based tools","volume":"41","author":"Quast","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.748253","article-title":"Gut microbes and hepatic encephalopathy: from the old concepts to new perspectives","volume":"9","author":"Rocco","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.gastha.2024.02.010","article-title":"Decreased abundance of genus Slackia in individuals with obesity and colorectal adenoma","volume":"3","author":"Sakai","year":"2024","journal-title":"Gastro Hep Adv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1111\/all.15440","article-title":"The abundance of Ruminococcus bromii is associated with faecal butyrate levels and atopic dermatitis in infancy","volume":"77","author":"Sasaki","year":"2022","journal-title":"Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1053\/j.gastro.2021.04.013","article-title":"Impact of antibiotic resistance genes in gut microbiome of patients with cirrhosis","volume":"161","author":"Shamsaddini","year":"2021","journal-title":"Gastroenterology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/0270-9139(95)90516-2","article-title":"Escherichia coli capsular polysaccharide and spontaneous bacterial peritonitis in cirrhosis","volume":"21","author":"Soriano","year":"1995","journal-title":"Hepatology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.550420","article-title":"Interpretations of environmental microbial community studies are biased by the selected 16S rRNA (gene) amplicon sequencing pipeline","volume":"11","author":"Straub","year":"2020","journal-title":"Front. Microbiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"20231261","DOI":"10.1098\/rspb.2023.1261","article-title":"Practical advice on variable selection and reporting using Akaike information criterion","volume":"290","author":"Sutherland","year":"2023","journal-title":"Proc. Biol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jhep.2025.06.019","article-title":"Effect of rifaximin in patients with severe cirrhosis and ascites: a randomized double-blind placebo-controlled clinical trial","volume":"83","author":"Th\u00e9venot","year":"2025","journal-title":"J. Hepatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41586-024-08095-4","article-title":"Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin","volume":"635","author":"Turner","year":"2024","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12967-023-04262-9","article-title":"Integrative analysis of the gut microbiota and faecal and serum short-chain fatty acids and tryptophan metabolites in patients with cirrhosis and hepatic encephalopathy","volume":"21","author":"Wang","year":"2023","journal-title":"J. Transl. Med."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168999","article-title":"The link between gut microbiota and hepatic encephalopathy","volume":"23","author":"Won","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac607","article-title":"Benchmarking differential abundance analysis methods for correlated microbiome sequencing data","volume":"24","author":"Yang","year":"2023","journal-title":"Brief Bioinform."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.761192","article-title":"Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome","volume":"11","author":"Yu","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1930709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:50:16Z","timestamp":1790661016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1930709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":41,"alternative-id":["10.3389\/fcimb.2026.1930709"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1930709","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1930709"}}